Compare F5 Inc (FFIV) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F5 Inc vs TransMedics Group Inc — how do they compare? F5 Inc trades at $415.62 (market cap $23.44B), while TransMedics Group Inc trades at $87.04 (market cap $3.10B). The key difference: F5 Inc is far larger — about 7.6× TransMedics Group Inc's market cap, and F5 Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| FFIV | TMDX | |
|---|---|---|
Market Cap | $23.44B | $3.10B |
Sector | Technology | Technology |
52-Week High | $431.26 | $150.42 |
52-Week Low | $223.99 | $61.99 |
Enterprise Value | $22.08B | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
F5 (FFIV) stock trades at $422.95, up 3.16% on the day, near its 52-week high. The company reported strong Q3 2026 earnings, beating estimates with EPS of $4.73 versus $4.00 expected, driven by 19% product revenue growth. Technical indicators show a bullish trend with support at $411 and resistance at $425. Fundamentals remain solid with revenue growth to $3.09B in 2025 and net income margin of 21.95%.
Outlook is positive given raised revenue guidance and robust cybersecurity demand, but valuation multiples like P/E of 32.98 suggest premium pricing. Risks include competitive pressures and execution challenges in sustaining high growth. Analyst consensus is Moderate Buy with a $430.43 price target, indicating modest upside potential from current levels.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
